Cabozantinib in combination w/ nivolumab and ipilimumab of IMDC intermediate or poor risk significantly improved PFS vs PBO

Lenvatinib plus pembro for aRCC - update on the CLEAR study

Abemaciclib plus NSAI for HR+, HER2- advanced breast cancer - MONARCH 3 interim data

Lasofoxifene vs fulvestrant for locally advanced/metastatic ER+/HER2- breast cancer: ELAINE trial

RADICALS-HD trial: androgen deprivation therapy with post-operative radiotherapy to treat prostate cancer

ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer

A new era of early cancer detection with blood test may change cancer screening paradigms

Metastatic breast cancer endpoints for survival: rwPFS and TTNT

Colorectal cancer and precision oncology

An overview of treatment advances in gastric cancer

Optimum treatment strategy algorithm for mCRC

Personalised smoking cessation support in a lung cancer screening programme